ABVC BioPharma amends convertible note; corrects conversion price, discloses placement agent warrants

ABVC BIOPHARMA, INC.

Secured convertible note $1.2M principal issued to Lind Global Fund II for $1M purchase price.
Conversion price amended to lesser of $3.50 fixed or 90% of avg of three lowest VWAPs in prior 20 days.
First 180 days conversions at fixed $3.50 price if no event of default, per amendment dated Jan 12, 2024.
Issued Allele Capital placement agent warrants for 30,000 shares at $2.00 per share.
Lender waives any prior events of default under the transaction documents.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ABVC BIOPHARMA, INC. amended amendment to the Note with Lind Global Fund II, LP.

Action: amendment
Agreement: notes offering
Counterparty: Lind Global Fund II, LP

Exact text from the filing

ntered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Lind Global Fund II, LP (“ Lind ”), pursuant to which the Company issued Lind a secured, convertible note in the principal amount of $1,200,000 (the “ Offering ”),

View on SEC.gov

Browse all material agreements →

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-004199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.